New treatment study for children with T-cell ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new treatment plan for children and teens newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). It aims to see if the approach is safe and works well, and might offer a more tailored therapy for this specific type of leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 month and 18 years old.
- You must have been diagnosed with T-cell acute lymphoblastic leukemia (T-ALL) using special tests on your bone marrow or blood cells.
- You must not have other types of leukemia like B-ALL or AML.
- You must not have major health problems like Down syndrome, heart disease, or severe infections.
- You must not have received certain cancer treatments (like chemotherapy, radiation, or steroids) in the past 1 to 3 months before the study starts.
- You must not have any other serious medical or mental health condition that could make the study unsafe or hard to follow.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia (ALL) that is intermediate or high risk. The goal is to find the best way to treat the cancer and improve outcomes.
This trial tests a new treatment plan for children and teens newly diagnosed with a specific type of leukemia called Philadelphia chromosome-positive B-ALL. The goal is to see if the approach improves outcomes.
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
This Phase 2 study tests whether venetoclax combined with azacitidine can treat newly diagnosed T-ALL, a type of leukemia. It may help reduce cancer activity and improve outcomes if you meet the safety and treatment timing requirements.
This trial tests a combination of venetoclax and azacytidine for people with certain types of T-cell acute lymphoblastic leukemia (T-ALL) that haven't been treated yet. It focuses on cases with specific genetic changes and aims to see if this drug pair can help control the disease.
This trial combines a kid-inspired chemotherapy backbone with a targeted pill (venetoclax) and immunotherapy (special antibodies) to treat adults with Ph-negative acute lymphoblastic leukemia (ALL). The goal is to use a more effective, less toxic approach developed for children.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.